跳至主要内容
临床试验/NCT02790853
NCT02790853进行中(未招募)早期 1 期

Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2016年5月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
进行中(未招募)
入组人数
63
试验地点
1
主要终点
Detection of high grade dysplasia and carcinoma

研究概览

简要总结

This early phase I trial studies how well multimodal imaging works for surveillance in patients with oral potentially malignant disorders. New types of imaging devices may help doctors decide if a lesion in the mouth is pre-cancerous or cancerous.

详细描述

PRIMARY OBJECTIVES:

I. To compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD).

SECONDARY OBJECTIVES:

I. To determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have images of sufficient quality.

II. To compare expression of molecular biomarkers to results from white light examination, multimodal imaging and pathologic assessment in a subset of patients who have invasive biopsies or resection.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who are willing to participate.
  • Adult subjects with: a. clinically evident oral premalignant lesion (OPL) or suspicious oral mucosal lesion. or b. pathologic diagnosis of dysplasia or c. history of resected oral cancer or d. oral potentially malignant disorder (OPMD) or e. history of tobacco and/or alcohol exposure.
  • Ability to understand and willingness to sign a written informed consent document (ICD).

排除标准

  • Known allergy to proflavine or acriflavine.
  • Pregnant females.

研究组 & 干预措施

Diagnostic (multimodal imaging, biopsy)

Experimental

Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.

干预措施: Biopsy (Procedure)

Diagnostic (multimodal imaging, biopsy)

Experimental

Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.

干预措施: Fluorescence Imaging (Procedure)

Diagnostic (multimodal imaging, biopsy)

Experimental

Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.

干预措施: High-Resolution Microendoscopy (Procedure)

Diagnostic (multimodal imaging, biopsy)

Experimental

Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.

干预措施: Proflavine Hemisulfate (Drug)

结局指标

主要结局

Detection of high grade dysplasia and carcinoma

时间窗: Up to 2 years

Will compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD).

次要结局

  • Diagnostic assessment(Up to 2 years)
  • Biomarker analysis(Up to 2 years)
  • Cytologic results(Up to 2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Advanced imaging for identifying chemotherapy-induced cardiac damage in lymphoma patientsHodgkin and non-Hodgkin lymphomaMedDRA version: 17.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 17.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 17.1Level: HLGTClassification code 10025322Term: Lymphomas non-Hodgkin's unspecified histologySystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 17.1Level: HLGTClassification code 10025321Term: Lymphomas non-Hodgkin's T-cellSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2014-002226-13-DKRigshospitalet100
进行中(未招募)
1 期
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and ChemotherapyAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia
NCT03422731City of Hope Medical Center82
已完成
1 期
The study is to assess the retinal biomarkers in patients diagnosed with macular telangiectasia.
CTRI/2018/03/012742Giridhar Eye Institute25
终止
1 期
Gastric In Vivo StudyGastric Cancer
NCT02207959Susana Gonzalez8
已完成
早期 1 期
Endoscopic Multispectral Imaging for the Early Detection of Barrett's NeoplasiaBarrett's EsophagusIntraepithelial Neoplasia
NCT01384864Anandasabapathy, Sharmila, M.D.30
Multimodal Imaging for Surveillance in Patients With... | 临床试验